484 related articles for article (PubMed ID: 27273731)
1. Effect of Adding Liraglutide vs Placebo to a High-Dose lnsulin Regimen in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Vanderheiden A; Harrison L; Warshauer J; Li X; Adams-Huet B; Lingvay I
JAMA Intern Med; 2016 Jul; 176(7):939-47. PubMed ID: 27273731
[TBL] [Abstract][Full Text] [Related]
2. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).
Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Ahrén B; Torffvit O; Attvall S; Ekelund M; Filipsson K; Tengmark BO; Sjöberg S; Pehrsson NG
BMJ; 2015 Oct; 351():h5364. PubMed ID: 26512041
[TBL] [Abstract][Full Text] [Related]
4. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
Lane W; Weinrib S; Rappaport J
Diabetes Technol Ther; 2011 May; 13(5):592-5. PubMed ID: 21406014
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity.
Li CJ; Li J; Zhang QM; Lv L; Chen R; Lv CF; Yu P; Yu DM
Cardiovasc Diabetol; 2012 Nov; 11():142. PubMed ID: 23153177
[TBL] [Abstract][Full Text] [Related]
7. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.
Mok J; Adeleke MO; Brown A; Magee CG; Firman C; Makahamadze C; Jassil FC; Marvasti P; Carnemolla A; Devalia K; Fakih N; Elkalaawy M; Pucci A; Jenkinson A; Adamo M; Omar RZ; Batterham RL; Makaronidis J
JAMA Surg; 2023 Oct; 158(10):1003-1011. PubMed ID: 37494014
[TBL] [Abstract][Full Text] [Related]
9. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J
JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653
[TBL] [Abstract][Full Text] [Related]
10. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Rubino DM; Greenway FL; Khalid U; O'Neil PM; Rosenstock J; Sørrig R; Wadden TA; Wizert A; Garvey WT;
JAMA; 2022 Jan; 327(2):138-150. PubMed ID: 35015037
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of a phase 3 randomized clinical trial.
Kaneko S; Nishijima K; Bosch-Traberg H; Kaku K; Seino Y
J Diabetes Investig; 2018 Jul; 9(4):840-849. PubMed ID: 29277968
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.
Tack CJ; Jacob S; Desouza C; Bain SC; Buse JB; Nauck MA; Petrie JR; Poulter NR; Pratley RE; Stegmann HVBK; Bosch-Traberg H; Startseva E; Zinman B;
Diabetes Obes Metab; 2019 Nov; 21(11):2450-2458. PubMed ID: 31282028
[TBL] [Abstract][Full Text] [Related]
13. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
; Nathan DM; Lachin JM; Balasubramanyam A; Burch HB; Buse JB; Butera NM; Cohen RM; Crandall JP; Kahn SE; Krause-Steinrauf H; Larkin ME; Rasouli N; Tiktin M; Wexler DJ; Younes N
N Engl J Med; 2022 Sep; 387(12):1063-1074. PubMed ID: 36129996
[TBL] [Abstract][Full Text] [Related]
14. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.
Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Svensson CK; Koyuncu K; Schjerning O; Oturai PS; Kjaer A; Nielsen J; Holst JJ; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
JAMA Psychiatry; 2017 Jul; 74(7):719-728. PubMed ID: 28601891
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.
Ahmann A; Rodbard HW; Rosenstock J; Lahtela JT; de Loredo L; Tornøe K; Boopalan A; Nauck MA;
Diabetes Obes Metab; 2015 Nov; 17(11):1056-64. PubMed ID: 26179619
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study.
Abreu M; Tumyan A; Elhassan A; Peicher K; Papacostea O; Dimachkie P; Siddiqui MS; Pop LM; Gunasekaran U; Meneghini LF; Adams-Huet B; Li X; Lingvay I
Diabetes Obes Metab; 2019 Sep; 21(9):2133-2141. PubMed ID: 31144435
[TBL] [Abstract][Full Text] [Related]
17. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of liraglutide on glycemic endpoints in people of Western European and South Asian descent with T2DM using multiple daily insulin injections: results of the MAGNA VICTORIA studies.
Bizino MB; Jazet IM; van Eyk HJ; Rensen PCN; Geelhoed-Duijvestijn PH; Kharagjitsingh AV; Paiman EHM; Smit JW; Lamb HJ
Acta Diabetol; 2021 Apr; 58(4):485-493. PubMed ID: 33399989
[TBL] [Abstract][Full Text] [Related]
19. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
[TBL] [Abstract][Full Text] [Related]
20. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
